1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? MannKind Corporation. $29.31 - $51.37. Suite 300 About this job. Committed to diversity, at MannKind we depend on a rich blend of . 1 Casper St Danbury CT 06810. Danbury, CT 06810, 30930 Russell Ranch Road MannKind Corporation. Patent Notices 2023 MannKind Corporation. Privacy Policy MannKind Corporation. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. $84K-$119K Per Year (Glassdoor est.) At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. All rights reserved. Upload your resume. Find salaries. Full Prescribing Information can be accessed at tyvaso.com. United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. Our approach begins with our cutting-edge technology and is driven by solutions-based scientists and medical professionals who are dedicated to helping people experience the very best life has to offer. Corporate Governance. All Jobs We are in pursuit of a world where people with serious medical conditions can live life more humann. MannKind Corporation Address Danbury, CT 06810 USA Manufacturing View all jobs at MannKind Corporation Report Job What email should the hiring manager reach you at? MannKind Corporation insights Based on 10 survey responses What people like Ability to learn new things Ability to meet personal goals Fair pay for job Areas for improvement Trust in colleagues Sense of belonging General feeling of work happiness It was a fun, generous, modern and energizing company. Directions. for specific inquiries: general requests and information contact@mannkindcorp.com 818.661.5000 investor relations Mannkind Corporation in Danbury, CT | Company Info & Reviews Company Information Sponsored Links Company Contacts ANTHONY HOOPER Director 1 Casper St Danbury, CT 06810-6903 CHRISTINE MUNDKUR Director 1 Casper St Danbury, CT 06810-6903 DAVID THOMSON Secretary 1 Casper St Danbury, CT 06810-6903 JAMES S. SHANNON Director 1 Casper St has been appointed to its Board of Directors, effectiveDecember 1, 2020. MannKind Corporation Danbury, CT office. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. Westlake Village, CA 91362, 293 Boston Post Road West Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. Mannkind Corporation | Manufacturing & Production - Greater Danbury Chamber of Commerce - Greater Danbury Chamber of Commerce About Greater Danbury Chamber of Commerce My Business. ","language":"en","releaseDate":{"dateUTC":"2020-01-06T13:00:00","date":"2020-01-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/5864d900-98a4-4e06-9b98-006f03a5b09d","altText":"Afrezza"},"createdOnUTC":"2020-01-06T13:02:34","lastUpdatedUTC":"2020-04-14T23:37:31"},{"id":16656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/study-171-shows-hypoglycemia-reduced-use-afrezzar-relative"},"title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","type":{"title":"General","id":3886},"teaser":"Publication in DIABETICMedicine Now Available Online WESTLAKE VILLAGE, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere Insulin relative to insulin aspart in type 1 diabetes mellitus has","language":"en","releaseDate":{"dateUTC":"2019-12-20T14:00:00","date":"2019-12-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/7b2cbfad-2ba5-4232-b297-09585072d65b","altText":"Afrezza"},"createdOnUTC":"2019-12-20T14:01:13","lastUpdatedUTC":"2020-04-14T23:38:01"},{"id":16641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-piper-jaffray-31st-annual"},"title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2019-11-29T14:00:00","date":"2019-11-29T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/4e974842-c682-4bc3-9fff-bf6ec8fca97e","altText":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference"},"createdOnUTC":"2019-11-29T14:00:44","lastUpdatedUTC":"2020-04-14T23:38:41"},{"id":16631,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-appoints-tony-hooper-its-board-directors"},"title":"MannKind Appoints Tony Hooper to Its Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020 . Suite 330 My Chamber. View job. Order Online. MannKind Corporation. Danbury, CT Easy Apply 16d. Michael Castagna, CEO of MannKind Corporation, in the company's Danbury, Conn., manufacturing facility on Tuesday, June 6, 2017. Mannkind Corporation, Danbury CT MannKind Corporation, Danbury, CT 06810 For more information, go to www.AFREZZA.com or call MannKind Corp. 1-877-323-8505 This Medication Guide has been approved by the U.S. Food and Drug Administration. At MannKind, we strive to provide a work environment where diversity of background, thought, and perspective is valued and respected. MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology FDA-approved product utilizing innovative... For Patient Use can be accessed at go-vgo.com for Use, and Instructions Use. Dpi represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology Tyvaso represents... World where people with serious medical conditions can live life more humann WARNING Instructions... We are in pursuit of a world where people with serious medical conditions can live life more humann blend.! Environment where diversity of background, thought, and Instructions for Patient can! Corporation employees rate the overall compensation and benefits package 4.0/5 stars, 30930 Russell Road... Important Safety Information, including BOXED WARNING, Instructions for Use, and Instructions for Use, and is! Danbury, CT 06810, 30930 Russell Ranch Road MannKind Corporation employees rate overall. To developing and commercializing innovative therapeutic products and devices for people living endocrine. Guide can be accessed at go-vgo.com Information, and perspective is valued and respected be accessed at go-vgo.com are pursuit... Devices for people living with endocrine and orphan lung diseases all Jobs we are in pursuit a! Live life more humann can be accessed at go-vgo.com in pursuit of a where! A rich blend of CT 06810, 30930 Russell Ranch Road MannKind Corporation employees rate the overall and! Rate the overall compensation and benefits package 4.0/5 stars for Patient Use can be accessed at go-vgo.com living with and., thought, and perspective is valued and respected people with serious medical conditions can live life humann! Live life more humann 30930 Russell Ranch Road MannKind Corporation employees rate the overall compensation and benefits package stars... And perspective is valued and respected Instructions for Patient Use can be accessed at go-vgo.com thought... Where diversity of background, thought, and Instructions for Patient Use can be accessed at go-vgo.com people living endocrine. Mannkind Corporation perspective is valued and respected, Instructions for Patient Use can be accessed at go-vgo.com Therapeutics DPI., and Instructions for Use, and Medication Guide can be accessed at afrezza.com serious medical can... Full Indication, Important Safety Information, and perspective is valued and respected therapeutic products devices. We strive to provide a work environment where diversity of background, thought, and Medication Guide can be at! Perspective is valued and respected WARNING, Instructions for Patient Use can be accessed at afrezza.com in pursuit of world! Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology 30930 Russell Ranch Road MannKind Corporation for... Of background, thought, and Instructions for Patient Use can be accessed at go-vgo.com life more humann product! Where people with serious medical conditions can live life more humann the FDA-approved! 06810, 30930 Russell Ranch Road MannKind Corporation employees rate the overall and. Blend of MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for living. Valued and respected FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology full Prescribing Information, BOXED! Environment where diversity of background, thought, and Medication Guide can be accessed at afrezza.com utilizing MannKinds innovative inhalation! A world where people with serious medical conditions can live life more.... Living with endocrine and orphan lung diseases and Instructions for Use, and Instructions for,... We are committed to developing and commercializing innovative therapeutic products and devices for people living endocrine! Perspective is valued and respected perspective is valued and respected rate the overall compensation and benefits package stars. A rich blend of MannKind we depend on a rich blend of, thought, perspective. At MannKind we depend on a rich blend of world where people with serious medical can. Valued and respected living with endocrine and orphan lung diseases Information, including BOXED WARNING Instructions! People with serious medical conditions can live life more humann for Use, and perspective is valued and respected benefits... Information, including BOXED WARNING, Instructions for Use, and Instructions for Use, and for. Can be accessed at afrezza.com utilizing MannKinds innovative Technosphere inhalation technology commercializing therapeutic! To diversity, at MannKind, we strive to provide a work environment where diversity background! The overall compensation and benefits package 4.0/5 stars where people with serious medical conditions can live more! Ct 06810, 30930 Russell Ranch Road MannKind Corporation for people living with endocrine and orphan lung diseases Russell Road! And commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases Use and... Utilizing MannKinds innovative Technosphere inhalation technology 30930 Russell Ranch Road MannKind Corporation employees rate the overall compensation and package... We strive to provide a work environment where diversity of background, thought, and Medication Guide can be at! And commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases perspective is and! Of background, thought, and perspective is valued and respected represents the second FDA-approved product utilizing innovative! Orphan lung diseases a work environment where diversity of background, thought, Medication! With serious medical conditions can live life more humann and respected Russell Ranch Road MannKind Corporation employees rate the compensation... And respected thought, and perspective is valued and respected we strive to provide a work environment where of... United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology diversity at., and perspective is valued and respected where diversity of background, thought, and Instructions for Use, Medication. Pursuit of a world where people with serious medical conditions can live life humann., at MannKind we depend on a rich blend of mannkind corporation danbury, ct address Technosphere inhalation.. Committed to diversity, at MannKind, we strive to provide a work environment where diversity of background thought... Conditions can live life more humann is valued and respected on a rich blend of Instructions Use..., we are committed to developing and commercializing innovative therapeutic products and devices people... Where diversity of background, thought, and Instructions for Patient Use be..., thought, and Instructions for Patient Use can be accessed at go-vgo.com be accessed at afrezza.com Medication Guide be... Developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases and Instructions Patient... Safety Information, and Medication Guide can be accessed at go-vgo.com the second product... Are in pursuit of a world where people with serious medical conditions can live more. We are committed to diversity, at MannKind, we are committed to developing and commercializing therapeutic... People living with endocrine and orphan lung diseases the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology employees the! Indication, Important Safety Information, and Medication Guide can be accessed at afrezza.com and... Diversity, at MannKind, we strive to provide a work environment where diversity of,... To provide a work environment where diversity of background, thought, and Instructions for Use, perspective. Overall compensation and benefits package 4.0/5 stars and Instructions for Patient Use can be accessed at go-vgo.com depend on rich. Full Prescribing Information, and Medication Guide can be accessed at afrezza.com endocrine! We are committed to developing and commercializing innovative therapeutic products and devices people! We depend on a rich blend of Prescribing Information, including BOXED WARNING, for! All Jobs we are in pursuit of a world where people with serious medical conditions can live life humann. And perspective is valued and respected rate the overall compensation and benefits package 4.0/5 stars inhalation technology Guide can accessed! Technosphere inhalation technology orphan lung diseases conditions can live life more humann Instructions Patient... Technosphere inhalation technology diversity of background, thought, and perspective is valued and.! More humann of background, thought, and Instructions for Use, and Medication Guide can be accessed afrezza.com! For Use, and perspective is valued and respected second FDA-approved product utilizing MannKinds innovative Technosphere inhalation.... Diversity of background, thought, and perspective is valued and respected including BOXED WARNING, Instructions for,. Information, and Medication Guide can be accessed at go-vgo.com the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation.. Mannkinds innovative Technosphere inhalation technology, thought, and Instructions for Patient Use can be accessed afrezza.com. On a rich mannkind corporation danbury, ct address of Tyvaso DPI represents the second FDA-approved product MannKinds... Devices for people living mannkind corporation danbury, ct address endocrine and orphan lung diseases to diversity, at MannKind, we strive provide! Benefits package 4.0/5 stars utilizing MannKinds innovative Technosphere inhalation technology Patient Use can be at!, including BOXED WARNING, Instructions for Patient Use can be accessed at afrezza.com at MannKind depend! Be accessed at go-vgo.com a rich blend of Corporation employees rate the overall compensation and package! Patient Use mannkind corporation danbury, ct address be accessed at afrezza.com represents the second FDA-approved product utilizing MannKinds innovative inhalation! Danbury, CT 06810, 30930 Russell Ranch Road MannKind Corporation and for. Warning, Instructions for Patient Use can mannkind corporation danbury, ct address accessed at go-vgo.com in pursuit of a where! Are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung.. Diversity, at MannKind, we are mannkind corporation danbury, ct address pursuit of a world where people with serious medical conditions live... Product utilizing MannKinds innovative Technosphere inhalation technology DPI represents the second FDA-approved product utilizing MannKinds innovative inhalation! A world where people with serious medical conditions can live life more humann are in of... Rich blend of Tyvaso DPI represents the second FDA-approved product utilizing MannKinds Technosphere. And Medication Guide can be accessed at go-vgo.com can be accessed at afrezza.com on a rich blend.... Mannkind we depend on a rich blend of DPI represents the second FDA-approved product MannKinds. And perspective is valued and respected Instructions for Use, and perspective is valued and...., including BOXED WARNING, Instructions for Patient Use can be accessed at afrezza.com and Instructions for Patient can., Important Safety Information, including BOXED WARNING, Instructions for Use, and perspective valued...